Fulcrum Therapeutics (FULC) Profit After Tax (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Profit After Tax data on file, last reported at -$18.9 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 7.0% year-over-year to -$18.9 million in Q1 2026; TTM through Mar 2026 was -$76.1 million, a 14816.08% decrease from a year earlier, with the FY2025 full-year figure at -$74.8 million, down 669.52% from the prior year.
• Profit After Tax for Q1 2026 stood at -$18.9 million, up from -$20.3 million in the prior quarter.
• Over the last five years, Profit After Tax for FULC reached as high as $55.4 million in Q2 2024 and fell as low as -$34.1 million in Q2 2022.
• Historically, Profit After Tax has averaged -$18.2 million across 5 years, with a median of -$23.7 million in 2022.
• Across the five-year window, Profit After Tax jumped 332.98% in 2024 and plunged 131.22% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$26.1 million in 2022, then gained by 7.81% to -$24.1 million in 2023, then soared by 31.24% to -$16.6 million in 2024, then slipped by 22.46% to -$20.3 million in 2025, then increased by 6.9% to -$18.9 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$18.9 million in Q1 2026, -$20.3 million in Q4 2025, and -$19.6 million in Q3 2025.